Author

A. G. Waks

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:whole-exome sequencing· 3 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:variant calling· 1

Frequent Co-Authors

E. P. Winer· 3 shared N. U. Lin· 3 shared N. Wagle· 3 shared O. Cohen· 3 shared D. Kim· 2 shared K. Helvie· 2 shared K. J. Kowalski· 2 shared M. R. Lloyd· 2 shared

Activity by Year

2019-2019 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. P. Winer

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

S. A. Wander, O. Cohen, X. Gong, G. N. Johnson, J. Buendia-Buendia, M. R. Lloyd, D. Kim, F. Luo, P. Mao, K. Helvie, K. J. Kowalski, U. Nayar, A. G. Waks, S. Parsons, R. Martinez, , N. Wagle

The paper identifies eight resistance mechanisms to CDK4/6 inhibitors in HR+ breast cancer, present in 80% of resistant tumors, with potential therapeutic strategies.

bioRxiv · Nov 28, 2019Cancer Biology

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

A. G. Waks, O. Cohen, B. Kochupurakkal, D. Kim, C. E. Dunn, J. Buendia Buendia, S. Wander, K. Helvie, M. R. Lloyd, L. Marini, M. E. Hughes, S. S. Freeman, S. P. Ivy, J. Geradts, S. Isakoff, , N. Wagle

This study identifies genomic reversion and increased DNA end resection as mechanisms of resistance to PARP inhibitors and platinum in BRCA1/2-mutant metastatic breast cancer, with RAD51 foci as a potential biomarker.

bioRxiv · Nov 10, 2019Cancer Biology

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

P. Mao, O. Cohen, K. J. Kowalski, J. G. Kusiel, J. E. Buendia-Buendia, M. S. Cuoco, P. Exman, S. A. Wander, A. G. Waks, U. Nayar, J. Chung, S. Freeman, O. Rozenblatt-Rosen, V. A. Miller, F. Federica Piccioni, , N. Wagle

This study identifies FGFR and FGF pathway alterations as acquired resistance mechanisms to ER-targeted therapy in ER+ metastatic breast cancer and suggests targeted inhibitors as potential treatments.

bioRxiv · Oct 7, 2019Cancer Biology